Recent Updates
Recently added Catalysts
LSTA Positive Sentiment

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences

Key Takeaway: Marea Therapeutics, a subsidiary of Lisata Therapeutics, announced its participation in several upcoming investor conferences. The presentations will take place at the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference in November. Marea's lead product candidate, MAR001, is currently in Phase 2b development for severe hypertriglyceridemia.

Market Sentiment Analysis

POSITIVE FACTORS

  • Marea Therapeutics will present at multiple investor conferences.
  • The company is developing next-generation medicines for cardioendocrine diseases.
  • MAR001 is in Phase 2b clinical development for severe hypertriglyceridemia.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
4.7%
average across 3 past catalysts
Cash runway
~9 mo
Medium dilution risk
Lead asset
CLBS14
Phase 2 · Myocardial Ischemia

Full Press Release Details

SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that management will participate in the following investor conferences:

Guggenheim Healthcare Innovation Conference Presentation: Tuesday, November 10 at 11:30 a.m. EST Boston, MA

LifeSci Growth and Innovation Summit 1x1 Meetings: Monday, November 16 London, U.K.

Jefferies Global Healthcare Conference London Presentation: Tuesday, November 17 at 8:00 a.m. GMT London, U.K.

Live webcasts of the presentations at the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference London will be available on the “Events & Presentations” section within the Investors page on the Lisata website. Replays of the webcasts will be available following each event.
About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead product candidate, MAR001, is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 for the treatment of acromegaly.
About Lisata Therapeutics Lisata Therapeutics is a clinical-stage pharmaceutical company. Following its acquisition of Marea, Lisata’s lead product candidate is MAR001, which is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 for the treatment of acromegaly.
Contacts:
Lisata:
Investors and Media: John Menditto jmenditto@lisata.com
Marea:

Frequently Asked Questions

What conferences will Marea Therapeutics attend?

Marea will attend the Guggenheim and Jefferies Global Healthcare Conferences.

What is MAR001 used to treat?

MAR001 is in development for severe hypertriglyceridemia.

When is the Guggenheim Healthcare Innovation Conference?

It is scheduled for November 10 at 11:30 a.m. EST.

Where is the LifeSci Growth and Innovation Summit held?

The summit will take place in London, U.K. on November 16.

Last updated: Nov 5, 2026